

RESEARCH

Open Access



The metabolome of male and female individuals with knee osteoarthritis is influenced by 18-months of weight loss intervention: the IDEA trial

Hope D. Welhaven¹, Avery H. Welfley², Brian Bothner¹, Stephen P. Messier⁴, Richard F. Loeser⁵ and Ronald K. June^{3*}

Abstract

Background The Intensive Diet and Exercise for Arthritis (IDEA) trial was a randomized trial conducted to evaluate the effects of diet and exercise on osteoarthritis (OA), the most prevalent form of arthritis. Various risk factors, including obesity and sex, contribute to OA's debilitating nature. While diet and exercise are known to improve OA symptoms, cellular and molecular mechanisms underlying these interventions, as well as effects of participant sex, remain elusive.

Methods Serum was obtained at three timepoints from IDEA participants assigned to groups of diet, exercise, or combined diet and exercise ($n = 10$ per group). A randomly selected subset of serum samples were extracted and analyzed via liquid chromatography-mass spectrometry combined with metabolomic profiling to unveil mechanisms associated with types of intervention and disease. Extracted serum was pooled and fragmentation patterns were analyzed to identify metabolites that statistically differentially regulated between groups.

Results Changes in metabolism across male and female IDEA participants after 18-months of diet, exercise, and combined diet and exercise intervention mapped to lipid, amino acid, carbohydrate, vitamin, and matrix metabolism. The diverse metabolic landscape detected across IDEA participants shows that intervention type differentially impacts the serum metabolome of OA individuals. Moreover, dissimilarities in the serum metabolome corresponded with participant sex.

Conclusions These findings suggest that intensive weight loss among males and females offers potential metabolic benefits for individuals with knee OA. This study provides a deeper understanding of dysregulation occurring during OA development in parallel with various interventions, potentially paving the way for improved interventions, treatments, and quality of life of those impacted by OA.

Trial Registration clinicaltrials.gov Identifier NCT00381290, Registered, 9/25/2006.

Keywords Osteoarthritis, Metabolism, Weight loss, Diet, Exercise, Obesity, Sex

*Correspondence:

Ronald K. June
rjune@montana.edu

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Background

Obesity is the most modifiable risk factor and is a known accelerant of osteoarthritis (OA) [1, 2]. Typically, weight loss via diet and exercise is recommended for obese OA patients with OA. Weight loss improves symptomatic knee OA [3, 4]. However, the cellular and molecular mechanisms underlying weight-loss-related symptom improvement remain elusive. OA affects both males and females, but knee OA is more severe and prevalent among females [5, 6]. Known female-specific OA risk factors include genetics, anatomy, and increased likelihood to sustain a traumatic knee injury compared to male counterparts [7, 8], although sexual dimorphism at the molecular and cellular levels remains unclear.

Metabolomics, the study of small molecule intermediates called metabolites, can provide insight into OA pathogenesis, patient risk factors, and metabolic perturbations caused by diet and exercise interventions. This powerful tool has been applied in other musculoskeletal studies to analyze the metabolism of various fluids and tissues (e.g., synovial fluid) during disease progression [9–13] and after mechanical loading [14–16]. Nuclear Magnetic Resonance (NMR) metabolomics provided insight into urine signatures in the multi-faceted and randomized Intensive Diet and Exercise for Arthritis (IDEA) trial. The IDEA trial was conducted to assess the effects of weight loss, via diet and exercise, on primary and secondary outcomes in OA participants [3, 4]. Using NMR metabolomics, dysregulated amino acid and lipid metabolism were found in a subset of IDEA urine samples from participants with radiographic progression compared to non-progressors [17]. While this study provided insight into disease progression based on urine profiles, further investigation using untargeted mass spectrometry-based metabolomics, as it provides improved sensitivity, increased quantification, assesses a wide range of compound, and is optimal for low sample volumes, is needed. With this approach, we can gain a better understanding of current weight loss interventions, the role of obesity

and sex, and underlying molecular mechanisms driving OA.

Therefore, the objectives of this study were to (1) compare serum global metabolomic profiles to analyze changes in metabolism over the course of 18-months of weight loss intervention, (2) illuminate metabolic pathways influenced by different types of interventions, and (3) identify signatures that are sex dependent.

Materials and methods

Study design, interventions, and participants

The participants in this study were a random subset of those enrolled in the IDEA trial - a single blind, single-center 18-month randomized controlled trial (NCT00381290, registration date 10/2006) - who had serum samples available from the three collection time points (pre-trial, 6-months, 18-months). In total, 30 participants were randomly selected with 10 participants per intervention group (Diet, D: *n*=10, Exercise, E: *n*=10, Diet and Exercise, DE: *n*=10). The rationale for analyzing this random subset was to perform a preliminary analysis to determine if apparent differences warrant analysis of the complete dataset in the future. To examine sex-associated differences, equal numbers of male and female participants were included (*n*=15 females, *n*=15 males, *n*=5 females/5 males per intervention group). The average BMI and age for the overall IDEA population was 33.58 and 65.60, respectively. In the present study, age and BMI measures for the participants randomly selected were representative of the overall IDEA population where the average BMI and age for the overall IDEA population was 33.6 and 65.6, respectively (Table 1). Race and ethnicity were not available for this study and were not assessed. Moreover, analyses and interpretation were limited by provided partial participant information. Information on radiographic damage scores, comorbidities, medications, and specific symptoms were not provided or analyzed in the present study.

The IDEA trial was conducted at Wake Forest University and Wake Forest School of Medicine between July 2006 and November 2011. This trial was a single-blind, 18-month, randomized controlled trial to determine whether a ≥10% loss in body weight induced by different intervention types would improve primary (e.g., knee joint compression forces and IL-6 levels) and secondary clinical outcomes (e.g., pain, function, mobility). Participants (*n*=454) were assigned to one of three interventions: diet (D), exercise (E), or diet and exercise (D+E). Additional details about intervention types, radiographic measurements, participant inclusion criteria, and study design are provided in the initial study reports [3, 4].

Table 1 Participant information for each intervention type. Baseline BMI and age are detailed for group and broken down by sex. Data are presented as mean ± standard deviation from the mean

	Exercise (E)	Diet (D)	Diet & exercise (D+E)	All IDEA participants
BMI	33.14 ± 2.03	33.39 ± 2.20	32.93 ± 2.83	32.60 ± 3.70
BMI Female	32.75 ± 2.52	32.75 ± 2.52	33.75 ± 3.27	
BMI Male	33.53 ± 1.58	34.02 ± 1.89	32.12 ± 2.37	
Age	65.99 ± 4.21	65.78 ± 4.34	65.89 ± 1.79	65.58 ± 6.19
Age Female	65.80 ± 5.26	65.80 ± 5.26	65.65 ± 0.62	
Age Male	66.19 ± 3.50	65.76 ± 3.86	66.11 ± 2.59	

Serum sampling, extraction, and metabolite profiling

Blood samples were collected during the IDEA trial from participants following a 10-hour fast at three different time points: baseline, 6-months, and 18-months [4]. At each time point, samples were collected, and serum was stored at -80°C until extraction. Thus, 90 serum samples were obtained from the randomly selected 30 participants for this study ($n=3$ serum samples – baseline, 6 months, 18 months – per participant) with 10 participants per intervention group ($n=5$ males, $n=5$ females). 100 μL of serum aliquots were centrifuged at 500xg for 5 min to remove cells and debris. Next, supernatant was transferred to a fresh mass-spectrometry grade microcentrifuge tube, 500 μL of high-performance liquid chromatography (HPLC) grade cold acetone were added, samples were vortexed vigorously, and chilled overnight at -80°C to precipitate proteins. The following day, serum samples were vortexed again, centrifuged at 16,100xg for 10 min, supernatant was evaporated by vacuum concentration to isolate metabolites. Once dry, metabolites were resuspended with 1:1 HPLC-grade acetonitrile: water.

Extracted serum samples ($n=90$) were injected and analyzed as previously described using liquid chromatography-mass spectrometry (LC-MS) [18]. Additionally, 10 pooled samples were subjected to liquid chromatography tandem mass spectrometry (LC-MS/MS) for metabolite identification purposes. LC-MS and LC-MS/MS instrumentation and operation is further detailed in supplemental methods. Data consisted of mass-to-charge ratios (m/z), metabolite abundances, and retention times which were processed using Agilent Masshunter Qualitative Analysis software and MSConvert [19]. Data were then exported and converted using XCMS [20]. Using in-house standardized procedures [21], MetaboAnalyst (version 5.0) was used to perform a suite of statistical analyses to visualize data, distinguish subsets of metabolite features that are co-regulated and dysregulated between groups. Additionally, the Mummichog algorithm within MetaboAnalyst was used to map key metabolites to cellular pathways. To correct for multiple comparisons and limit false discoveries, significance was determined using false discovery rate (FDR)-corrected p -values with an a priori corrected threshold of $p < 0.05$. Finally, analysts were blinded throughout the study from randomization, extraction, to metabolomic profiling statistical analyses in order to minimize bias and maximize the validity of the results.

Results

Changes in BMI and weight after 18-months of intensive weight loss interventions

For the overall IDEA trial, 88% of patients completed the trial [4]. Both changes in weight and BMI over 18 months were calculated for all participants selected for

this analysis ($n=30$, $n=10$ per intervention) (Supplemental Fig. 1). At baseline, 96.7% of participants selected for metabolomics had a BMI of 30 or greater. At 18 months, 62.5% of D+E participants, 40.0% of D participants, and 22.2% of E participants had a BMI less than 30. Considering weight loss, D+E ($\downarrow 11.8\%$, $p=0.012$) and D ($\downarrow 9.4\%$, $p=0.0075$) participants lost more weight than the E group ($\downarrow 3.9\%$, $p=0.2973$) (Supplemental Table 1) [3, 4].

Weight loss and BMI measures for participant selected for this analysis were representative of the overall IDEA population ($n=454$) [4]. Beyond the average weight loss per group, the amount of weight loss independent of group assignment was examined. Specifically, ranges of weight loss were categorized into 0–5%, 5–10%, 10%+ and weight gained and was determined to not influence metabolic results (Supplemental Table 1). However, sample size may limit conclusions and requires investigation among a larger subset of IDEA participants. Of the participants selected for this analysis, one E participant had a net weight loss of zero, and one participant from the D and D+E groups gained weight over 18 months. Weight loss data was not available for four participants in the randomly selected participants for this analysis (Supplemental Table 1).

Weight loss interventions differentially influence the serum metabolome over 18 months

To examine variations in metabolism over the course of the 18-month period in response to three interventions – D, E, D+E – we performed a preliminary analysis of metabolite feature intensity changes between timepoints. For each co-detected metabolite feature, we calculated the change in intensity (delta values) by subtracting the baseline intensity from the 6-month intensity, as well as the change from 6-months to 18-months, on a per-participant bases. While some transitory changes were observed between shorter intervals, more durable shifts emerged between baseline and 18-months. Consequently, the delta values between baseline and 18-month metabolite feature intensities were used for analysis throughout this study to examine intervention- and sex-associated differences. Across all intervention groups 2,142 unique metabolite features were co-detected. Principle Component Analysis (PCA)—an unsupervised multivariate test that reduces the dimensionality of a large dataset to identify patterns—and Partial Least Squares-Discriminant Analysis (PLS-DA)—a supervised multivariate test—were used to analyze global metabolic differences in the calculated delta change values across the three intervention groups: diet (D), exercise (E), and combined diet and exercise (D+E).

PCA displays some overlap between groups with principal components (PC) 1 and 2 representing 32.3% of the total variability between groups (Fig. 1A). PLS-DA shows




Fig. 1 Metabolomic profiles differ between intervention groups after 18-months. **(A)** Principal component analysis (PCA), an unsupervised multivariate test, displays overlap of intervention groups in 2D, whereas **(B)** Partial least squares-discriminant analysis (PLS-DA), a supervised multivariate test, displays less overlap of interventions suggesting that the metabolome of participants assigned to different intervention groups for 18-months are distinct from each other. **(C)** A group median heatmap analysis of the top 25 PLS-DA Variable in Importance Projection Scores, visualized using hierarchical clustering, highlights that exposure to 18-months of different interventions are associated with distinct metabolic regulation patterns. **(D)** Clusters of coregulated metabolite features (1–6) derived from participants serum across interventions underwent pathway enrichment analysis revealing distinct metabolic patterns that are associated with intervention type. Cooler colors (blue) and warmer colors (yellow) indicate lower and higher metabolite intensities relative to the mean. Colors in **A–D** correspond to: green – diet (**D**); purple – exercise (**E**); blue – diet and exercise (**D + E**)

greater separation and minimal overlap of groups with components 1 and 2 accounting for 5.2% and 12% of the variability, respectively (Fig. 1B), suggesting that changes in metabolism reflect intervention type. A median metabolite intensity heatmap was used to perform additional analysis on the metabolite features with the 25

highest VIP scores (Fig. 1C). VIP scores are calculated by summing the squared correlations between PLS-DA components and the original value and the metabolite feature. Of these 25 metabolites, 11 were more abundant in D participants, whereas 13 were more abundant in E participants and 1 was more abundant in D+E

participants. Interestingly, the metabolite feature intensities in the D+E group overlap with those detected in the D and E group. The heatmap analysis of the top 25 VIP metabolite features demonstrated substantial metabolic differences between intervention types (Fig. 1C).

To assess pathways affected by these interventions, we performed functional pathway enrichment analysis. First, we created a median metabolite intensity heatmap using delta values to distinguish clusters of similarly or differentially regulated metabolites on a global scale (Fig. 1D). These clusters were analyzed using MetaboAnalyst's Functional Analysis feature to underpin any significant pathways (false discovery rate adjusted p -values ≤ 0.05). Metabolite features highest in abundance among D+E participants and lowest in D participants mapped to xenobiotics metabolism, R-group synthesis, various fatty acid metabolisms, vitamin E metabolism, carnitine shuttle-related metabolism, and cytochrome P450 metabolism. Comparatively, metabolite features highest in D+E participants and lowest in both D and E groups mapped to di-unsaturated fatty acid beta-oxidation, linoleate metabolism, dynorphin metabolism, glycerophospholipid biosynthesis and metabolism, and squalene and cholesterol biosynthesis. Features highest in D+E participants and lowest in the E participants mapped to polyunsaturated fatty acid biosynthesis, glycerophospholipid metabolism, biopterin metabolism, alkaloid biosynthesis, and fatty acid activation and oxidation.

Metabolite features highest in abundance among D participants and lowest in both the D+E and E participants mapped to metabolism of vitamin metabolism (B6, C), carbohydrate and sugar metabolism (hexose, starch, sucrose, fructose, mannose), lipid-related pathways (glycerophospholipid, glycosphingolipid, omega-6), N-glycan biosynthesis and degradation, as well as pathways related to energy metabolism (pentose phosphate, glycolysis, gluconeogenesis). Metabolites features highest in abundance among E participants and lowest in D+E and D groups mapped to amino group metabolism (glutamate, histidine, methionine, cysteine, tryptophan, alanine, and aspartate), nitrogen metabolism, purine metabolism, vitamin B3 metabolism, and metabolisms involved with the formation of putative anti-inflammatory metabolites from eicosapentaenoic acid. Finally, metabolites highest in both E and D groups and lowest in D+E participants mapped to various amino group metabolisms (glycine, serine, threonine, arginine, proline, alanine, aspartate, lysine, and asparagine), N-glycan degradation, urea cycle, butanoate metabolism, chondroitin sulfate degradation, keratan sulfate degradation, heparan sulfate degradation, and cytochrome P450 metabolism (Table 2).

Additionally, pairwise comparisons using delta change values between the three intervention groups were performed to further investigate how weight loss

interventions differentially influence OA metabolism (Supplemental Fig. 2, Supplemental Table 2). Specifically, PCA and PLS-DA were used to visualize the metabolomes of participants and is detailed in supplemental results. Populations of metabolite features distinguished by fold change when comparing intervention groups underwent pathway analyses. Pathways associated with both D+E and E groups included N-glycan biosynthesis and ubiquinone and other terpenoid-quinone biosynthesis. All other overlapping pathways were associated with both D and E participants which included aminoacyl-tRNA biosynthesis, cytochrome P450 metabolism, purine metabolism, and glutathione metabolism. No significant pathways were associated exclusively with either the D or E participants (Supplemental Table 3). Additionally, populations of metabolite features distinguished by fold change when comparing intervention groups were matched against metabolite identifications made using LC-MS/MS data. Many of these were detected across comparisons and displayed diverse regulation patterns (Supplemental Table 4). Altogether, the results show that different weight loss interventions influence OA metabolism in distinct ways.

Serum metabolome differs by sex after 18-months of intervention

To examine potential sexual dimorphism within the serum metabolome, PCA, PLS-DA, fold change, and volcano plot analyses were used to compare male and female participants, both in general and within intervention groups. PCA comparison of all male and female participants finds overlap with principal components 1 and 2 accounting for more than 30% of the variability in the dataset. PLS-DA reveals distinct endotypes based on sex, with components 1 and 2 accounting for 19.6% of the variability (Fig. 2A-B). Fold change revealed that 283 metabolites had a greater change ($FC > 2$) in abundance during the 18-month period in female participants than in male participants, mapping to glycolysis/gluconeogenesis, ubiquinone and other terpenoid-quinone biosynthesis, various amino acid metabolisms, and metabolism of starch and sucrose. Comparatively, 345 features had a greater change in abundance during the 18-month period in male participants than female participants, and these metabolites mapped to purine metabolism (Fig. 2C, Supplemental Table 5).

Likewise, a pairwise comparison was conducted between male and female D+E participants. PCA finds some overlap of male and female participants, with PCs 1 and 2 accounting for 47.3% of the total variability (Fig. 3A). PLS-DA, however, finds complete separation of participants based on sex with components 1 and 2 representing 26% of the variability (Fig. 3B). Among female participants, 586 metabolites had at least a 2-fold greater

Table 2 Metabolic pathways associated with diet, exercise, and diet and exercise interventions identified by median metabolite intensity heatmap analysis. All reported pathways have a FDR-corrected significance level < 0.05. D = diet. E = exercise. DE = diet and exercise. Clusters defined in Fig. 1D

Cluster	Highest	Lowest	Pathway
1	D+E	D	Xenobiotics metabolism
1	D+E	D	R Group Synthesis
1	D+E	D	Fatty acid oxidation, peroxisome
1	D+E	D	Fatty acid oxidation
1	D+E	D	Fatty acid activation
1	D+E	D	Vitamin E metabolism
1	D+E	D	De novo fatty acid biosynthesis
1	D+E	D	Omega-6 fatty acid metabolism
1	D+E	D	Carnitine shuttle
1	D+E	D	Drug metabolism - cytochrome P450
2	D+E	D, E	Di-unsaturated fatty acid beta-oxidation
2	D+E	D, E	Linoleate metabolism
2	D+E	D, E	Dynorphin metabolism
2	D+E	D, E	Glycerophospholipid metabolism
2	D+E	D, E	Squalene and cholesterol biosynthesis
2	D+E	D, E	Glycosphingolipid biosynthesis - ganglioseries
3	D+E	E	Polyunsaturated fatty acid biosynthesis
3	D+E	E	Glycerophospholipid metabolism
3	D+E	E	Biopterin metabolism
3	D+E	E	Alkaloid biosynthesis II
3	D+E	E	Fatty acid oxidation
3	D+E	E	Fatty acid activation
4	D	D+E, E	Phosphatidylinositol phosphate metabolism
4	D	D+E, E	Propanoate metabolism
4	D	D+E, E	Vitamin B6 (pyridoxine) metabolism
4	D	D+E, E	Glycolysis and Gluconeogenesis
4	D	D+E, E	Tryptophan metabolism
4	D	D+E, E	N-Glycan biosynthesis
4	D	D+E, E	Starch and Sucrose Metabolism
4	D	D+E, E	Mono-unsaturated fatty acid beta-oxidation
4	D	D+E, E	Ascorbate (Vitamin C) and Aldarate Metabolism
4	D	D+E, E	Lipoate metabolism
4	D	D+E, E	Purine metabolism
4	D	D+E, E	Fructose and mannose metabolism
4	D	D+E, E	Hexose phosphorylation
4	D	D+E, E	Vitamin H (biotin) metabolism
4	D	D+E, E	Biopterin metabolism
4	D	D+E, E	Caffeine metabolism
4	D	D+E, E	Glycerophospholipid metabolism
4	D	D+E, E	Pentose phosphate pathway
4	D	D+E, E	Glycosphingolipid metabolism
4	D	D+E, E	Pyrimidine metabolism
4	D	D+E, E	Galactose metabolism
4	D	D+E, E	Glycosphingolipid biosynthesis - globoseries
4	D	D+E, E	Porphyryn metabolism
4	D	D+E, E	N-Glycan Degradation
4	D	D+E, E	Omega-6 fatty acid metabolism
5	E, D	D+E	Urea cycle/amino group metabolism
5	E, D	D+E	Glycine, serine, alanine and threonine metabolism
5	E, D	D+E	Drug metabolism - cytochrome P450
5	E, D	D+E	Arginine and Proline Metabolism

Table 2 (continued)

Cluster	Highest	Lowest	Pathway
5	E, D	D+E	Butanoate metabolism
5	E, D	D+E	Lysine metabolism
5	E, D	D+E	Drug metabolism - other enzymes
5	E, D	D+E	N-Glycan Degradation
5	E, D	D+E	Chondroitin sulfate degradation
5	E, D	D+E	Keratan sulfate degradation
5	E, D	D+E	Heparan sulfate degradation
5	E, D	D+E	Beta-Alanine metabolism
5	E, D	D+E	Alanine and Aspartate Metabolism
5	E, D	D+E	Aspartate and asparagine metabolism
6	E	D+E, D	Glutamate metabolism
6	E	D+E, D	Glutathione Metabolism
6	E	D+E, D	Putative anti-Inflammatory metabolites formation from eicosapentaenoic acid
6	E	D+E, D	Nitrogen metabolism
6	E	D+E, D	Histidine metabolism
6	E	D+E, D	Biopterin metabolism
6	E	D+E, D	Pyrimidine metabolism
6	E	D+E, D	Methionine and cysteine metabolism
6	E	D+E, D	Tryptophan metabolism
6	E	D+E, D	Purine metabolism
6	E	D+E, D	Vitamin B3 (nicotinate and nicotinamide) metabolism
6	E	D+E, D	Alanine and Aspartate Metabolism




Fig. 2 Serum metabolome of all IDEA participants, excluding the factor of intervention, is influenced by participant sex. **(A)** While PCA displays overlapping of male and female IDEA participants **(B)** PLS-DA improves clustering of participants within their respective sex group suggesting the serum metabolome is sexually dimorphic. **(C)** Fold change analysis was conducted to pinpoint populations of metabolite features that are differentially regulated between males and females. This revealed 283 metabolite features that had a FC > 2 and were higher in abundance in female participants, whereas 345 had a FC < -2 and were higher in abundance in male participants. The colors in **A-C** correspond to: pink – females, blue – males

change in abundance during the 18-month period than they did in male participants. These metabolites mapped to tryptophan metabolism, glycosaminoglycan degradation, biosynthesis of unsaturated fatty acids, and caffeine metabolism. 532 features had at least a 2-fold increase in male participants. These mapped to aminoacyl-tRNA biosynthesis, lysine degradation, various amino acid metabolisms, and glutathione metabolism (Fig. 3C, Supplemental Table 5).

Among E participants, PCA shows some overlap between male and female participants, with PCs 1 and 2 accounting for 44.7% of the total variability (Fig. 3D).

PLS-DA shows complete separation of groups with components representing 25% of the variability (Fig. 3E). Among female participants, 433 metabolites had a 2-fold or greater change in abundance compared to male participants, mapping to significant enrichment of caffeine metabolism. 617 metabolite features had a greater change in male participants compared to female participants, mapping significant enrichment of valine, leucine, and isoleucine biosynthesis (Fig. 2E, Supplemental Table 5).

Finally, in D participants, PCA shows overlap between male and female participants, with the first two PCs accounting for 43.2% of variability in the dataset (Fig. 2G).




Fig. 3 Global analysis of intervention groups after 18-months reveals that the serum metabolome is influenced by sex. **(A)** PCA displayed some overlap of D+E males and females whereas **(B)** PLS-DA perfectly separated D+E males and females suggesting that the serum metabolome is potentially influenced by participant sex. **(C)** Fold change analysis identified 568 metabolite features that had a FC > 2 and were higher in abundance in D+E females. Conversely, 532 had a FC < -2 and were higher in abundance in D+E males. Similarly **(D)** PCA, **(E)** PLS-DA, and **(F)** fold change was applied and revealed a similar sexual dimorphic pattern when comparing male and female E participants. This same suite of analyses was applied to examine sex-associated metabolic patterns between male and female D participants **(G-I)**. Populations of metabolite features distinguished by fold change analyses were then subjected to functional pathway enrichment analyses to pinpoint biological pathways. Considering differences in metabolic regulation associated with sex across D+E **(A-C)**, E **(D-F)** and E **(G-I)** participants, it is evident that that serum metabolome of IDEA participants is influenced by sex. The colors in **A-I** correspond to: light and dark blue – female and male diet and exercise **(A+E)** participants; light and dark purple – female and male exercise **(E)** participants; light and dark green – female and male diet participants

PLS-DA shows complete separation of groups with components representing 29% of the variability (Fig. 2H). Additionally, 524 metabolites had a 2-fold or greater change in abundance in female participants than they did in male participants. These mapped to significant enrichment of aminoacyl-tRNA biosynthesis, and valine, leucine, and isoleucine biosynthesis. 632 features had a greater change in male participants, mapping to significant enrichment of purine metabolism (Fig. 2I, Supplemental Table 6). Notably, D+E, D, and E male and female participants differed at baseline, further supporting the

sexual dimorphic nature of OA generally and within the context of weight loss intervention (Supplemental Fig. 3).

Populations distinguished through fold change analyses assessing sexual dimorphism across intervention groups (Fig. 3) were matched against LC-MS/MS identified metabolites. Notably, many of these identified metabolites were statistically significant across pairwise comparisons between interventions and were sex-associated. Of these, docasanedioic acid showcased consistently higher abundance patterns in all female participants within each intervention groups. Excluding D male and

female participants, stearyl carnitine was higher in abundance in female participants when comparing metabolic patterns associated with sex within the E and D+E groups. Strikingly, N-acetyldemethylphosphinothricin was detected when investigating both intervention- and sex-associated differences. Specifically, it was higher in male participants when examining sex differences within intervention groups. However, when considering interventions only, it was the highest among D participants compared to E and D+E participants (Supplemental Table 4). In summation, the data vividly illustrates the striking divergence in serum metabolism between male and female participants subjected to different weight loss interventions.

Discussion

This metabolomics study, in conjunction with the overarching IDEA trial, demonstrates that intensive weight loss intervention, including diet and combined diet and exercise influences the metabolome of OA patients differently from exercise. When comparing participants after 18-months of exercise alone, dietary weight loss alone or the combination of the two, differences in energy, vitamin, carbohydrate, amino acid, and lipid metabolism were detected. Moreover, these data demonstrate clear metabolic differentiation between IDEA participants based on participant sex. Overall, intensive weight loss interventions influence the serum metabolome of OA individuals, and sex may independently influence the nature of metabolic changes in OA. The integration of the present metabolomic profiles with the previously reported IDEA study outcomes [4, 17] enhances the understanding of the effects of dietary weight loss and exercise in individuals with OA and provides insights into intervention effectiveness and potential biomarker identification.

Previously, NMR metabolomics was used to assess urine from IDEA participants finding detected metabolites corresponding to energy, amino acid, and lipid metabolisms. The present study using untargeted LC-MS-based metabolomics detected similar metabolic themes in serum extracts across intervention groups. D+E participants exhibited elevated lipid-related pathways such as the carnitine shuttle compared to both D and E participants (Table 2). The carnitine shuttle's primary function is to facilitate transport of fatty acids into the mitochondria for breakdown and ATP generation via beta-oxidation, which may explain why a prior study finds that short-term consumption of a high fat diet increases levels of circulating fatty acids and carnitines, further suggesting a link between diet and carnitine levels [22]. Specific to OA, some inflammatory fatty acids have been implicated in the pathogenesis of OA and higher concentrations of carnitines are observed in

synovium from end-stage knee OA patients [23]. Additionally, L-carnitine supplementation is a potential treatment to mitigate OA-related inflammation and oxidative stress [24, 25]. Taken together, carnitine may play a protective role in joint metabolism by facilitating fatty acid transport into the mitochondria for oxidation, though the exact mechanisms remain unknown.

After 18-months of intervention, D+E participants exhibited alterations in several noteworthy lipid-related pathways such as polyunsaturated fatty acid (PUFA) biosynthesis, omega-6 fatty acid metabolism, linoleate metabolism, and glycerophospholipid metabolism after 18-months of intervention. Omega-3 and -6 fatty acids, along with linoleic acid, a polyunsaturated omega-6, have all been implicated in the pathogenesis of OA [26, 27] and are also known to possess anti-inflammatory properties [28]. Glycosphingolipids, a key membrane component, have been previously linked to exercise, obesity, metabolic syndrome, and insulin resistance [29–31].

The dysregulation observed in membrane and inflammatory-related pathways could be attributed to exercise intervention in both E and D+E participants, as exercise has been demonstrated to modulate lipid profiles and metabolism [32], reduce plasma lipid levels [33], chronic inflammation [34], and antioxidant enzymes [35]. These findings suggest that the combination of diet and exercise act on pathways like the carnitine shuttle, PUFA, and glycosphingolipid metabolism, thereby influencing fat utilization for energy production, oxidative processes, and inflammatory functions.

D participants had elevated glycolysis, pentose phosphate pathway, purine and pyrimidine metabolism, and various sugar and vitamin metabolisms compared to E and D+E participants (Table 2). Purine levels are largely influenced by the purine content of food and influence the biosynthesis of pyrimidines. Notably, uric acid, the end-product of purine metabolism has powerful antioxidant effects in plasma [36]. The rate-limiting enzyme for uric acid production is xanthine oxidoreductase (XOR). Uric acid and XOR play a dual role: while uric acid is a powerful antioxidant, excess levels are dangerous and have been associated with hyperuricemia and cardiac disease. Additionally, XOR, in certain forms, can produce reactive oxygen and nitrogen species and is thought to contribute to metabolic syndrome via oxidative stress and inflammatory responses [37]. Plasma XOR activity has been associated with obesity, dyslipidemia, insulin resistance, indicating it is a novel biomarker of metabolic disorders [38]. Glycolysis and the pentose phosphate pathway play central roles in central energy metabolism as well as production of nucleotides (purines and pyrimidines) and amino acid precursors, oxidative stress reduction, and ATP generation. Disruptions in these pathways as a result of poor diet may lead to insufficient

ATP, NADH accumulation, inflammation, generation of reactive oxygen species, and may manifest as metabolic disorders.

Carbohydrate pathways like starch and sucrose metabolism are linked to central energy metabolism, possibly serving as biofuels for ATP production. Notable related pathways are hexose phosphorylation and vitamin C metabolism which were both detected among D participants. Vitamin C is a hexose derivative from glucose that has antioxidant capabilities and serves as a defense against reactive oxygen species, is critical for collagen synthesis by enhancing pro-collagen hydroxylation and has been hypothesized to have a protective role in OA [25, 39, 40]. Moreover, a study that investigated the association between vitamin C and knee OA found that low intake of vitamin C is a potential risk factor for KOA [40]. However, neither vitamin intake nor serum concentration was measured in this study. Additionally, likely variability in participant meal and snack choices warrants further investigation to understand the relationship between vitamin and carbohydrate metabolism, diet intervention, and OA.

Exercise is a common treatment for improving symptoms of obesity and related conditions such as cardiovascular disease, type II diabetes, and OA [41, 42]. Additionally, the anti-inflammatory effects of exercise have been well documented [43–45]. This could explain the elevated detection of putative anti-inflammatory and amino acid pathways including glutamate, histidine, alanine, aspartate, methionine, cysteine, and glutathione metabolism across E participants compared to D+E and D participants. Thus, the finding that these pathways were highest in E participants and detected in lower abundances in both D and D+E participants suggests that these metabolic changes are as a result of the diet. Notably, cysteine and glutamate are essential to produce glutathione, a key antioxidant that helps scavenge reactive oxygen species produced during normal cell metabolism and has been hypothesized to play a key role in the inflammatory response in OA [46]. Oxidative status, as reflected by the ratio of cysteine, glycine, and glutamate, tends to decrease with age, thereby increasing stress and cell death in chondrocytes [47]. Therefore, detection of glutathione, cysteine, and glutamate metabolism may reflect oxidative stress resistance in the presence of exercise. Moreover, amino acids like alanine, aspartate, and glutamate have been previously associated with OA and have been detected in higher concentrations among OA patients [48]. Histidine concentration distinguishes between the synovial fluid of OA and RA patients [49] and decreases as OA progresses [50]. Taken together, these findings suggest that metabolism of these amino acids may undergo significant changes in response to exercise in OA patients, suggesting amino acids could

potentially be monitored overtime to oversee OA development. Moreover, additional research and validation of these findings and the incorporation of non-OA individuals on these same weight loss interventions and OA individuals not on any kind of weight loss intervention is needed to better understand the relationship between amino acid metabolism, weight loss interventions, and OA.

While it is recognized that knee OA is more common and often more severe in female patients [5, 6], metabolic differences associated with knee OA that differ by sex remain uncertain. An increasing number of studies find sexual dimorphism in the context of OA and contribute mounting evidence indicating that the etiology and progression of OA may exhibit sex-specific changes as shown in these data. Divergent pathways between male and female IDEA participants mapped to glycolysis/gluconeogenesis, amino acid metabolism, and lipid-related metabolisms (Supplemental Table 5).

Sex-dependent differences in bone size and angle and pelvis and joint size are well documented [51, 52]. At the hormonal level, females have greater circulating levels of estrogen with levels fluctuating throughout the menstrual cycle and post-menopause. Thus, it is not surprising that these varying hormone levels appear to influence the serum metabolome. Both E and D+E female participants had elevated caffeine metabolism compared to male participants. For pre- and post-menopausal women, hormonal cycles may affect amino acid metabolism where protein oxidation is impacted by estrogen levels [53]. Understanding these sex-related metabolic differences could refine current OA prevention and treatment strategies, thus additional studies incorporating larger groups of males and females with and without OA is needed.

This study is not without limitations. First, this study lacks serum from both healthy controls and individuals with OA who did not undergo an intervention. Second, serum-derived metabolomic data may reflect joint health and provide insight into the effects of intervention and sex. However, the relationship between serum and synovial fluid is complex with many metabolites correlated between these compartments but many more metabolites without correlations [54, 55]. As such, the relationship between joint health and the serum metabolomic requires further investigation. A third limitation is the relatively small samples size of 10 individuals per intervention group which was necessitated by the time and cost of performing an extensive metabolomics analysis, thus validation studies are needed to further examine these findings and investigate the relationship between weight loss and metabolic pathways and mechanisms. Lastly, a well-known limitation of untargeted metabolomics using LC-MS/MS is that not all metabolite features can be identified, thus, additional targeted analyses are

needed to comprehensively examine OA metabolism and the effects of interventions.

The outcomes of this comprehensive metabolomics investigation, in conjunction with the overarching findings of the IDEA study, emphasize that intensive weight loss interventions have symptomatic and potential metabolic benefits among individuals with knee OA. Metabolic perturbations associated with these interventions, as well as patient sex, likely play a role in OA development and should be considered for downstream treatment strategies. By further applying metabolomics in parallel with these findings a greater understanding of the joint-level dysregulation during OA progression may shed light on the impacts of obesity, weight reduction, patient treatments, and interventions. Expansion with larger sample sizes will delve into the associations between other measurements obtained throughout the duration of the IDEA study and metabolomic results among all study participants. These insights hold promise for enhancing the current approach to managing and improving the quality of life of those affected by OA.

Abbreviations

OA	Osteoarthritis
IDEA	Intensive Diet and Exercise for Arthritis
NMR	Nuclear magnetic resonance
D	Diet
E	Exercise
D+E	Diet and exercise
FDR	False discovery rate
LC-MS	Liquid chromatography-mass spectrometry
LC-MS/MS	Liquid chromatography tandem mass spectrometry
m/z	Mass-to-charge ratio
HCA	Hierarchical clustering analysis
PCA	Principal component analysis
PLS-DA	Partial least squares-discriminant analysis
PUFA	Polyunsaturated fatty acid

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12891-024-08166-7>.

Supplementary Material 1

Supplementary Material 2

Acknowledgements

We thank the Montana State University Mass Spectrometry Facility including Dr. Donald Smith and Jesse Thomas for aiding in LC-MS analysis and interpretation. Additionally, authors thank Brady Hislop for his assistance in developing analysis pipelines and analyzing data.

Author contributions

HDW and RKJ designed metabolomics experiments; RFL and SPM designed trial parameters; HDW performed metabolite extractions; HWD ran LC-MS samples; HDW and AHW analyzed data; HWD, AHW, BB, STP, RFL, and RKJ interpreted results; HDW, AHW, and RKJ drafted manuscript. All authors have read and revised the manuscript.

Funding

This study was supported by grants from the National Institutes of Health (NIAMS R01AR073964 and R01AR081489) and the National Science Foundation (CMMI 1554708).

Data availability

Raw data can be found in supplemental material in Supplement Table 6.

Declarations

Ethics approval and consent to participate

The IDEA study was conducted at Wake Forest University, approved by the human subjects committee of Wake Forest Health Sciences, and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained in writing from all participants.

Competing interests

Dr. June owns stock in Beartooth Biotech and OpenBioWorks. Neither company was involved in this study.

Patient consent for publication

Consent to participate was provided in writing. Consent for publication is not applicable.

Conflict of interest

Authors have no conflicts of interest to disclose. Dr. June owns stock in Beartooth Biotech and OpenBioWorks, which were not involved in this study.

Author details

¹Department of Chemistry & Biochemistry and Molecular Biosciences Program, Montana State University, Bozeman, MT 59717, USA

²Department of Microbiology and Immunology, Montana State University, Bozeman, MT, USA

³Department of Mechanical & Industrial Engineering, Montana State University, PO Box 173800, Bozeman, MT 59717-3800 |, USA

⁴J.B. Snow Biomechanics Lab, Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC 27109, USA

⁵Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC 27599, USA

Received: 19 July 2024 / Accepted: 6 December 2024

Published online: 20 December 2024

References

1. Neogi T. The epidemiology and impact of pain in osteoarthritis. *Osteoarthritis Cartilage*. 2013;21(9):1145–53.
2. Bitton R. The economic burden of osteoarthritis. *Am J Manag Care*. 2009;15(8 Suppl):S230–235.
3. Messier SP, Legault C, Mihalko S, Miller GD, Loeser RF, DeVita P, Lyles M, Eckstein F, Hunter DJ, Williamson JD, et al. The intensive Diet and Exercise for Arthritis (IDEA) trial: design and rationale. *BMC Musculoskelet Disord*. 2009;10:93.
4. Messier SP, Mihalko SL, Legault C, Miller GD, Nicklas BJ, DeVita P, Beavers DP, Hunter DJ, Lyles MF, Eckstein F, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. *JAMA*. 2013;310(12):1263–73.
5. Blaker CL, Ashton DM, Doran N, Little CB, Clarke EC. Sex- and injury-based differences in knee biomechanics in mouse models of post-traumatic osteoarthritis. *J Biomech*. 2021;114:110152.
6. Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. *Osteoarthritis Cartilage*. 2005;13(9):769–81.
7. Loughlin J. Familial inheritance of osteoarthritis: documented family subsets. *Clin Orthop Relat Res*. 2004;427 Suppl:S22–25.
8. O'Connor MI. Sex differences in osteoarthritis of the hip and knee. *J Am Acad Orthop Surg*. 2007;15(Suppl 1):S22–25.
9. Carlson AK, Rawle RA, Wallace CW, Adams E, Greenwood MC, Bothner B, June RK. Global metabolomic profiling of human synovial fluid for rheumatoid arthritis biomarkers. *Clin Exp Rheumatol*. 2019;37(3):393–9.
10. Carlson AK, Rawle RA, Wallace CW, Brooks EG, Adams E, Greenwood MC, Olmer M, Lotz MK, Bothner B, June RK. Characterization of synovial fluid metabolomic phenotypes of cartilage morphological changes associated with osteoarthritis. *Osteoarthritis Cartilage*. 2019;27(8):1174–84.

11. Hugle T, Kovacs H, Heijnen IA, Daikeler T, Baisch U, Hicks JM, Valderrabano V. Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. *Clin Exp Rheumatol*. 2012;30(2):240–5.
12. Kim S, Hwang J, Kim J, Ahn JK, Cha HS, Kim KH. Metabolite profiles of synovial fluid change with the radiographic severity of knee osteoarthritis. *Joint Bone Spine*. 2017;84(5):605–10.
13. Zhang W, Likhodii S, Zhang Y, Aref-Eshghi E, Harper PE, Randell E, Green R, Martin G, Furey A, Sun G, et al. Classification of osteoarthritis phenotypes by metabolomics analysis. *BMJ Open*. 2014;4(11):e006286.
14. Jutila AA, Zignego DL, Hwang BK, Hilmer JK, Hamerly T, Minor CA, Walk ST, June RK. Candidate mediators of chondrocyte mechanotransduction via targeted and untargeted metabolomic measurements. *Arch Biochem Biophys*. 2014;545:116–23.
15. Salinas D, Murney BM, June RK. Physiological dynamic compression regulates central energy metabolism in primary human chondrocytes. *Biomech Model Mechanobiol*. 2019;18(1):69–77.
16. Zignego DL, Hilmer JK, June RK. Mechanotransduction in primary human osteoarthritic chondrocytes is mediated by metabolism of energy, lipids, and amino acids. *J Biomech*. 2015;48(16):4253–61.
17. Loeser RF, Pathmasiri W, Sumner SJ, McRitchie S, Beavers D, Saxena P, Nicklas BJ, Jordan J, Guermazi A, Hunter DJ, et al. Association of urinary metabolites with radiographic progression of knee osteoarthritis in overweight and obese adults: an exploratory study. *Osteoarthritis Cartilage*. 2016;24(8):1479–86.
18. Welhaven HD, Vahidi G, Walk ST, Bothner B, Martin SA, Heveran CM, June RK. The cortical bone metabolome of C57BL/6J mice is sexually dimorphic. *JBMR Plus*. 2022;6(7):e10654.
19. Kessner D, Chambers M, Burke R, Agus D, Mallick P. ProteoWizard: open source software for rapid proteomics tools development. *Bioinformatics*. 2008;24(21):2534–6.
20. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. *Anal Chem*. 2006;78(3):779–87.
21. Brahmachary PP, Welhaven HD, June RK. Metabolomic profiling to Understand Chondrocyte Metabolism. *Methods Mol Biol*. 2023;2598:141–56.
22. Moholdt T, Parr EB, Devlin BL, Debik J, Giskeodegard G, Hawley JA. The effect of morning vs evening exercise training on glycaemic control and serum metabolites in overweight/obese men: a randomised trial. *Diabetologia*. 2021;64(9):2061–76.
23. Adams SB Jr, Setton LA, Kensicki E, Bolognesi MP, Toth AP, Nettles DL. Global metabolic profiling of human osteoarthritic synovium. *Osteoarthritis Cartilage*. 2012;20(1):64–7.
24. Baghban F, Hosseinzadeh M, Mozaffari-Khosravi H, Dehghan A, Fallahzadeh H. The effect of L-Carnitine supplementation on clinical symptoms, C-reactive protein and malondialdehyde in obese women with knee osteoarthritis: a double blind randomized controlled trial. *BMC Musculoskelet Disord*. 2021;22(1):195.
25. Malek Mahdavi A, Mahdavi R, Kolahi S. Effects of L-Carnitine supplementation on serum inflammatory factors and matrix metalloproteinase enzymes in females with knee osteoarthritis: a Randomized, Double-Blind, placebo-controlled pilot study. *J Am Coll Nutr*. 2016;35(7):597–603.
26. Bastiaansen-Jenniskens YM, Siawash M, van de Lest CH, Verhaar JA, Kloppenburg M, Zuurmond AM, Stojanovic-Susulic V, Van Osch GJ, Clockaerts S. Monounsaturated and Saturated, but not n-6 polyunsaturated fatty acids decrease Cartilage Destruction under Inflammatory conditions: a preliminary study. *Cartilage*. 2013;4(4):321–8.
27. Oliviero F, Lo Nigro A, Bernardi D, Giunco S, Baldo G, Scanu A, Sfriso P, Ramonda R, Plebani M, Punzi L. A comparative study of serum and synovial fluid lipoprotein levels in patients with various arthritides. *Clin Chim Acta*. 2012;413(1–2):303–7.
28. Veras ASC, Gomes RL, Almeida Tavares ME, Giometti IC, Cardoso A, da Costa Aguiar Alves B, Lenquiste SA, Vanderlei LCM, Teixeira GR. Supplementation of polyunsaturated fatty acids (PUFAs) and aerobic exercise improve functioning, morphology, and redox balance in prostate obese rats. *Sci Rep*. 2021;11(1):6282.
29. Hla T, Dannenberg AJ. Sphingolipid signaling in metabolic disorders. *Cell Metab*. 2012;16(4):420–34.
30. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. *Cell Metab*. 2007;5(3):167–79.
31. Merrill AH Jr. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. *Chem Rev*. 2011;111(10):6387–422.
32. Monteiro PA, Chen KY, Lira FS, Saraiva BT, Antunes BM, Campos EZ, Freitas IF Jr. Concurrent and aerobic exercise training promote similar benefits in body composition and metabolic profiles in obese adolescents. *Lipids Health Dis*. 2015;14:153.
33. Mann S, Beedie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. *Sports Med*. 2014;44(2):211–21.
34. Liao MT, Liu WC, Lin FH, Huang CF, Chen SY, Liu CC, Lin SH, Lu KC, Wu CC. Intradialytic aerobic cycling exercise alleviates inflammation and improves endothelial progenitor cell count and bone density in hemodialysis patients. *Med (Baltim)*. 2016;95(27):e4134.
35. Urso ML, Clarkson PM. Oxidative stress, exercise, and antioxidant supplementation. *Toxicology*. 2003;189(1–2):41–54.
36. Johnson RJ, Lanaspa MA, Gaucher EA. Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations. *Semin Nephrol*. 2011;31(5):394–9.
37. Battelli MG, Bortolotti M, Polito L, Bolognesi A. The role of xanthine oxidoreductase and uric acid in metabolic syndrome. *Biochim Biophys Acta Mol Basis Dis*. 2018;1864(8):2557–65.
38. Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. *Am J Physiol Endocrinol Metab*. 2020;319(5):E827–34.
39. Plotnikoff R, Karunamuni N, Lytyvak E, Penfold C, Schopf flocher D, Imayama I, Johnson ST, Raine K. Osteoarthritis prevalence and modifiable factors: a population study. *BMC Public Health*. 2015;15:1195.
40. Sanghi D, Mishra A, Sharma AC, Raj S, Mishra R, Kumari R, Natu SM, Agarwal S, Srivastava RN. Elucidation of dietary risk factors in osteoarthritis knee-a case-control study. *J Am Coll Nutr*. 2015;34(1):15–20.
41. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. *Nat Rev Immunol*. 2011;11(9):607–15.
42. Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. *Scand J Med Sci Sports*. 2006;16(Suppl 1):3–63.
43. Cerqueira E, Marinho DA, Neiva HP, Lourenco O. Inflammatory effects of High and Moderate Intensity Exercise-A systematic review. *Front Physiol*. 2019;10:1550.
44. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. *J Appl Physiol* (1985). 2005;98(4):1154–62.
45. Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-Goetz L, et al. Position statement. Part one: Immune function and exercise. *Exerc Immunol Rev*. 2011;17:6–63.
46. Surapaneni KM, Venkataramana G. Status of lipid peroxidation, glutathione, ascorbic acid, vitamin E and antioxidant enzymes in patients with osteoarthritis. *Indian J Med Sci*. 2007;61(1):9–14.
47. Carlo MD Jr, Loeser RF. Increased oxidative stress with aging reduces chondrocyte survival: correlation with intracellular glutathione levels. *Arthritis Rheum*. 2003;48(12):3419–30.
48. Anderson JR, Chokesuwattanaskul S, Phelan MM, Welting TJM, Lian LY, Peffers MJ, Wright HL. (1)H NMR metabolomics identifies underlying Inflammatory Pathology in Osteoarthritis and rheumatoid arthritis synovial joints. *J Proteome Res*. 2018;17(11):3780–90.
49. Kim S, Hwang J, Kim J, Lee SH, Cheong YE, Lee S, Kim KH, Cha HS. Metabolic discrimination of synovial fluid between rheumatoid arthritis and osteoarthritis using gas chromatography/time-of-flight mass spectrometry. *Metabolomics*. 2022;18(7):48.
50. Zhang Q, Li H, Zhang Z, Yang F, Chen J. Serum metabolites as potential biomarkers for diagnosis of knee osteoarthritis. *Dis Markers*. 2015;2015:684794.
51. Barnett SC, Murray MM, Flannery SW, Team BT, Menghini D, Fleming BC, Kiapour AM, Proffen B, Sant N, Portilla G, et al. ACL size, but not signal intensity, is influenced by sex, body size, and Knee Anatomy. *Orthop J Sports Med*. 2021;9(12):23259671211063836.
52. Leong A. Sexual dimorphism of the pelvic architecture: a struggling response to destructive and parsimonious forces by natural & mate selection. *McGill J Med*. 2006;9(1):61–6.
53. Wohlgenuth KJ, Arieta LR, Brewer GJ, Hoselton AL, Gould LM, Smith-Ryan AE. Sex differences and considerations for female specific nutritional strategies: a narrative review. *J Int Soc Sports Nutr*. 2021;18(1):27.

54. Wallace CW, Hislop B, Hahn AK, Erdogan AE, Brahmachary PP, June RK. Correlations between metabolites in the synovial fluid and serum: a mouse injury study. *J Orthop Res*. 2022;40(12):2792–802
55. Zhang W, Likhodii S, Aref-Eshghi E, Zhang Y, Harper PE, Randell E, Green R, Martin G, Furey A, Sun G, et al. Relationship between blood plasma and synovial fluid metabolite concentrations in patients with osteoarthritis. *J Rheumatol*. 2015;42(5):859–65.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.